BMJ Best Practice

参考文献

关键文献

Di Nisio M, Wichers IM, Middeldorp S. Treatment for superficial thrombophlebitis of the leg. Cochrane Database Syst Rev. 2018 Feb 25;(2):CD004982.

Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis. 9th ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e419S-94S.

参考文章

1.  Anderson FA Jr., Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT Study. Arch Intern Med. 1991 May;151(5):933-8.

2.  Hanson JN, Ascher E, DePippo P, et al. Saphenous vein thrombophlebitis (SVT): a deceptively benign disease. J Vasc Surg. 1998 Apr;27(4):677-80.

3.  Nordstrom M, Lindblad B, Bergqvist D, et al. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med. 1992 Aug;232(2):155-60.

4.  Di Nisio M, Wichers IM, Middeldorp S. Treatment for superficial thrombophlebitis of the leg. Cochrane Database Syst Rev. 2018 Feb 25;(2):CD004982.

5.  Widmer LK, Stahelin HB, Nissen C, et al. Venen-, Arterien-krankheiten, koronare Herzkrankheit bei Berufstatigen: Prospektivepidemiologische Untersuchung. Basler studie I-III, 1959-1978. Bern, Switzerland: Huber; 1981.

6.  Unno N, Mitsuoka H, Uchiyama T, et al. Superficial thrombophlebitis of the lower limbs in patients with varicose veins. Surg Today. 2002;32(5):397-401.

7.  Lofgren EP, Lofgren KA. The surgical treatment of superficial thrombophlebitis. Surgery. 1981 Jul;90(1):49-54.

8.  Belcaro G, Nicolaides AN, Errichi BM, et al. Superficial thrombophlebitis of the legs: a randomized, controlled, follow-up study. Angiology. 1999 Jul;50(7):523-9.

9.  Decousus H, Epinat M, Guillot K, et al. Superficial vein thrombosis: risk factors, diagnosis and treatment. Curr Opin Pulm Med. 2003 Sep;9(5):393-7.

10.  Zollinger RW, Williams RD, Briggs DO. Problems in the diagnosis and treatment of thrombophlebitis. Arch Surg. 1962;85:34-40.

11.  Husni EA, Williams WA. Superficial thrombophlebitis of lower limbs. Surgery. 1982 Jan;91(1):70-4.

12.  Decousus H, Quéré I, Presles E, et al. Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Ann Intern Med. 2010 Feb 16;152(4):218-24.

13.  Nasr H, Scriven JM. Superficial thrombophlebitis (superficial venous thrombosis). BMJ. 2015 Jun 22;350:h2039.

14.  Samlaska CP, James WD. Superficial thrombophlebitis. I. Primary hypercoagulable states. J Am Acad Dermatol. 1990;22:975-989.

15.  Lutter KS, Kerr TM, Roedersheimer LR, et al. Superficial thrombophlebitis diagnosed by duplex scanning. Surgery. 1991 Jul;110(1):42-6.

16.  Leon L, Giannoukas AD, Dodd D, et al. Clinical significance of superficial vein thrombosis. Eur J Vasc Endovasc Surg. 2005 Jan;29(1):10-7.

17.  Martinelli I, Cattaneo M, Taioli E, et al. Genetic risk factors for superficial vein thrombosis. Thromb Haemost. 1999 Oct;82(4):1215-7.

18.  Schonauer V, Kyrle PA, Weltermann A, et al. Superficial thrombophlebitis and risk for recurrent venous thromboembolism. J Vasc Surg. 2003 Apr;37(4):834-8.

19.  de Godoy JM, Batigalia F, Braile DM. Superficial thrombophlebitis and anticardiolipin antibodies: report of association. Angiology. 2001 Feb;52(2):127-9.

20.  Sarica-Kucukoglu R, Akdag-Kose A, Kayabali M, et al. Vascular involvement in Behcet's disease: a retrospective analysis of 2319 cases. Int J Dermatol. 2006 Aug;45(8):919-21.

21.  Samlaska CP, James WD. Superficial thrombophlebitis. II. Secondary hypercoagulable states. J Am Acad Dermatol. 1990 Jul;23(1):1-18.

22.  Munavalli GS, Weiss RA. Complications of sclerotherapy. Semin Cutan Med Surg. 2007 Mar;26(1):22-8.

23.  Uurto I, Hannukainen J, Aarnio P. Single-center experience with foam sclerotherapy without ultrasound guidance for treatment of varicose veins. Dermatol Surg. 2007 Nov;33(11):1334-9.

24.  Van Den Bos RR, Neumann M, De Roos KP, et al. Endovenous laser ablation-induced complications: review of the literature and new cases. Dermatol Surg. 2009 Aug;35(8):1206-14.

25.  James KV, Lohr JM, Deshmukh RM, et al. Venous thrombotic complications of pregnancy. Cardiovasc Surg. 1996;4:777-782.

26.  Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med. 2004;164:1965-1976.

27.  Tepper NK, Marchbanks PA, Curtis KM. Superficial venous disease and combined hormonal contraceptives: a systematic review. Contraception. 2016 Sep;94(3):275-9.

28.  Coon WW, Willis PW 3rd, Keller JB. Venous thromboembolism and other venous disease in the Tecumseh community health study. Circulation. 1973;48:839-846.

29.  Coon WW. Risk factors in pulmonary embolism. Surg Gynecol Obstet. 1976;143:385-390.

30.  Goldhaber SZ, Savage DD, Garrison RJ, et al. Risk factors for pulmonary embolism: the Framingham Study. Am J Med. 1983;74:1023-1028.

31.  Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA. 1997;277:642-645.

32.  de Moerloose P, Wutschert R, Heinzmann M, et al. Superficial vein thrombosis of lower limbs: influence of factor V Leiden, factor II G20210A and overweight. Thromb Haemost. 1998;80:239-241.

33.  Primrose JN, Davies JA, Prentice CR, et al. Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity. Thromb Haemost. 1992;68:396-399.

34.  Gorski G, Noszczyk W, Kostewicz W, et al. Progress of local symptoms of superficial vein thrombosis vs. duplex findings. Vasa. 2004 Nov;33(4):219-25.

35.  Marchiori A, Mosena L, Prandoni P. Superficial vein thrombosis: risk factors, diagnosis, and treatment. Semin Thromb Hemost. 2006 Oct;32(7):737-43.

36.  Neher JO, Safranek S, Greenwald JL. Clinical inquiries: what is the best therapy for superficial thrombophlebitis? J Fam Pract. 2004 Jul;53(7):583-5.

37.  Gjores JE. Surgical therapy of ascending thrombophlebitis in the saphenous system. Angiology. 1962 May;13:241-3.

38.  Blumenberg RM, Barton E, Gelfand ML, et al. Occult deep venous thrombosis complicating superficial thrombophlebitis. J Vasc Surg. 1998 Feb;27(2):338-43.

39.  Barrelier MI. Thromboses veineuses superficielles des membres inferieurs. Actual Vasc Int. 1993;17:7-9.

40.  Bergqvist D, Jaroszewski H. Deep vein thrombosis in patients with superficial thrombophlebitis of the leg. Br Med J (Clin Res Ed). 1986;292:658-659.

41.  Gillet JL, Perrin M, Cayman R. Superficial venous thrombosis of the lower limbs: prospective analysis of 100 patients [in French]. J Mal Vasc. 2001;26:16-22.

42.  Bounameaux H, Reber-Wasem MA. Superficial thrombophlebitis and deep vein thrombosis: a controversial association. Arch Int Med. 1997;157:1822-1824.

43.  Hedderich GS, O'Connor RJ, Reid EC, et al. Caval tumor thrombus complicating renal cell carcinoma: a surgical challenge. Surgery. 1987;102:614-621.

44.  Siegelman ES, Needleman L. Venous thrombosis and cancer . N Engl J Med. 1993;328:885-887.

45.  Hettiarachchi RJ, Lok J, Prins MH, et al. Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. Cancer. 1998;83:180-185.

46.  Quenet S, Laporte S, Decousus H, et al. Factors predictive of venous thrombotic complications in patients with isolated superficial vein thrombosis. J Vasc Surg. 2003;38:944-949.

47.  Rodriguez-Peralto JL, Carrillo R, Rosales B, et al. Superficial thrombophlebitis. Semin Cutan Med Surg. 2007;26:71-76.

48.  University of Washington School of Medicine. Recommendations for management of superficial vein thrombosis. April 2015. https://depts.washington.edu/ (last accessed 4 November 2016).

49.  Wells PS, Owen C, Doucette S, et al. Does this patient have deep vein thrombosis? JAMA. 2006;295:199-207.

50.  Pulliam CW, Barr SL, Ewing AB. Venous duplex scanning in the diagnosis and treatment of progressive superficial thrombophlebitis. Ann Vasc Surg. 1991;5:190-195.

51.  Chengelis DL, Bendick PJ, Glover JL, et al. Progression of superficial venous thrombosis to deep vein thrombosis. J Vasc Surg. 1996;24:745-749.

52.  Jorgensen JO, Hanel KC, Morgan AM, et al. The incidence of deep venous thrombosis in patients with superficial thrombophlebitis of the lower limbs. J Vasc Surg. 1993;18:70-73.

53.  Decousus H, Prandoni P, Mismetti P, et al. Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med. 2010;363:1222-1232.

54.  Superficial Thrombophlebitis Treated by Enoxaparin Study Group. A pilot randomized double-blind comparison of a low-molecular-weight heparin, a nonsteroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Arch Int Med. 2003;163:1657-1663.

55.  Titon JP, Auger D, Grange P, et al. Therapeutic management of superficial venous thrombosis with calcium nadroparin: dosage testing and comparison with a non-steroidal anti-inflammatory agent [in French]. Ann Cardiol Angeiol (Paris). 1994;43:160-166.

56.  Di Nisio M, Peinemann F, Porreca E, et al. Treatment for superficial infusion thrombophlebitis of the upper extremity. Cochrane Database Syst Rev. 2015;(11):CD011015.

57.  Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis. 9th ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e419S-94S.

58.  Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315-352.

59.  Beyer-Westendorf J, Schellong SM, Gerlach H, et al. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol. 2017 Mar;4(3):e105-13.

60.  Scottish Intercollegiate Guidelines Network. Prevention and management of venous thromboembolism. October 2014 [internet publication].

61.  Rathbun SW, Aston CE, Whitsett TL. A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis. J Thromb Haemost. 2012;10:833-839.

62.  Bergqvist D, Brunkwall J, Jensen N, et al. Treatment of superficial thrombophlebitis: a comparative trial between placebo, Hirudoid cream and piroxicam gel. Ann Chir Gynaecol. 1990;79:92-96.

63.  Marchiori A, Verlato F, Sabbion P, et al. High versus low dose of unfractionated heparin for the treatment of superficial thrombophlebitis of the leg: a prospective, controlled, randomized study. Haematologica. 2002;87:523-527.

64.  Ferrari E, Pratesi C, Scaricabarozzi I. A comparison of nimesulide and diclofenac in the treatment of acute superficial thrombophlebitis. Drugs. 1993;46(suppl 1):197-199.

65.  Werth S, Bauersachs R, Gerlach H, et al. Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial. J Thromb Thrombolysis. 2016 Aug;42(2):197-204.

66.  Bing RJ, Lomnicka M.Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events? J Am Coll Cardiol. 2002 Feb 6;39(3):521-2.

67.  Wichers IM, Di Nisio M, Büller HR, et al. Treatment of superficial vein thrombosis to prevent deep vein thrombosis and pulmonary embolism: a systematic review. Haematologica. 2005;90:672-677.

68.  Cosmi B, Filippini M, Campana F, et al; STEFLUX Investigators. Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum). Thromb Res. 2014;133:196-202.

69.  Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest. 2001 Jan;119(suppl 1):108S-21S.

70.  Steinmeyer J. Pharmacological basis for the therapy of pain and inflammation with nonsteroidal anti-inflammatory drugs. Arthritis Res. 2000;2(5):379-85.

使用此内容应接受我们的免责声明